Current status and perspectives of the immunotherapy of leishmaniasis

Israel Medical Association Journal

Volumn 11, Issue 10, 2009, Pages 623-628

  El On, Joseph ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Chemotherapy; Immunology; Immunotherapy; Leishmaniasis

Indexed keywords

ALLOPURINOL; ALPHA INTERFERON; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIOXIDANT; BCG VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; ELONGATION FACTOR; FLUCONAZOLE; GAMMA INTERFERON; IMIQUIMOD; ITRACONAZOLE; KETOCONAZOLE; LEISH 110F; LEISHMACOL; LEISHMANIA VACCINE; LEVAMISOLE; LIPOSOME; LIQUID NITROGEN; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PHOSPHORYL LIPID A; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; SQUALENE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; Z 100;

ANTIBIOTIC RESISTANCE; CAUTERIZATION; CLIMATOTHERAPY; CRYOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; INFRARED RADIATION; LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA TROPICA; LEISHMANIASIS; NONHUMAN; PHOTODYNAMIC THERAPY; PROPHYLAXIS; REVIEW; SENSITIZATION; STANDARDIZATION;

ANIMALS; ANTIPROTOZOAL AGENTS; HUMANS; IMMUNOTHERAPY; LEISHMANIA; LEISHMANIASIS; PROTOZOAN VACCINES;

EID: 70350630449     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the forecoming 25 years. Vaccine 2008; 26: 1709-1724
2. von Stebut E, Udey MC. Requirements for Th1-dependent immunity against infection with L. major. Microb Infect 2004; 6: 1102-1109 (Pubitemid 39233683)
3. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420: 502-507
4. Salhi A, Rodrigues VJr, Santoro F, et al. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol 2008; 180: 6139-6148
5. Cabrera M, Shaw MA, Sharples C, et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995; 182: 1259-1264
6. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharmaceut Des 2002; 8: 319-342
7. Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian leishmaniasis. Am J Trop Med Hyg 2008; 78: 210-211
8. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 2007; 3: 733-740 (Pubitemid 350162073)
9. Gamier T, Croft CL. Topical treatment of cutaneous leishmaniasis. Curr Opin Invest Drugs 2002; 3: 538-544
10. Jha TK. Drug unresponsiveness and combination therapy for kala-azar. Indian J Med Res 2006; 123: 389-398
11. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus pentamidine in antimony unresponsive kala-azar. Lancet 1992; 340: 1256-1257
12. Thakur CP, Kanyok TP, Pandey AK, Sungh GP, Messik C, Olliaro P. Treatment of visceral leishmaniasis with injectible paromomycin (aminosidine). An open label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 2000; 94: 432-433 (Pubitemid 30662356)
13. Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008; 47: 1000-1006
14. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J. Safety, immunnogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 2004; 22: 1320-1326 (Pubitemid 38296677)
15. Musa AM, Khalil EA, Mahgoub FA, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 2008; 102: 58-63. (Pubitemid 350177425)
16. Machado-Pinto J, Pinto J, da Costa CA, et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int J Dermatol 2002; 41: 73-78 (Pubitemid 34552351)
17. Convit J, Ulrich M, Zerpa O, et al. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-1999. Trans R Soc Trop Med Hyg 2003; 97: 469-472
18. Convit J, Ulrich M, Polegre MA, et al. Therapy of Venezuelan patients with severe or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin - preliminary report. Mem Inst Oswaldo Cruz 2004; 99: 57-62. (Pubitemid 38406266)
19. Mayrink W, Botelho ACC, Magalhaes PA, et al. Immunotherapy, immunochemotherapy for American cutaneous leishmaniasis. Rev Soc Brasil Med Trop 2006; 39: 14-21.
20. El-On J, Livishin R, Hamburger D, Even-Paz Z. Weinrauch L. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986; 87: 284-288
21. Borja-Cabrera GP, Cruz Mendes A, Paraguai de Souza E, et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004; 22: 2234-2243
22. Santos FN, Borja-Cabera GP, Miyashiro LM, et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Vaccine 2007; 25: 6176-6190 (Pubitemid 47090200)
23. Lemesre JL, Holzmuller P, Goncalves RB, et al. Long-lasting protection against visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomized efficacy field trial. Vaccine 2007; 25: 4223-4234 (Pubitemid 46661824)
24. Miret J, Nascimento E, Sampaio W, et al. Evaluation of an immunochemotherapeutic protocol constituted N-methyl meglumine antimonite Leish-110f® + MPL-SE® vaccine to treat canine visceral leishmaniasis. Vaccine 2008; 26: 1585-1594
25. Sundar S, Rosenkaimer F, Lesser ML, Murray HW. immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J Infect Dis 1995; 171: 992-996
26. Badaro R, Falcoff E, Badaro FS, et al. Treatment of visceral leishmaniasis with antimony and interferon γ. N Engl J Med 1990; 322: 16-21. (Pubitemid 20023828)
27. Squires KE, Rosenkaimer F, Sherwood JA, Forni AL, Were JB, Murray HW. Immunochemotherapy of visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon gamma. Am J Trop Med Hyg 1993; 48: 666-669 (Pubitemid 23187196)
28. Badaro R, Lobo I, Munos A, et al. Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis 2006; 194: 1151-1159
29. Almeida RP, Brito J, Machado PL, et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am J Trop Med Hyg 2005; 73: 79-81. (Pubitemid 41278752)
30. Barroso PA, Marco JD, Calvopina M, Kato H, Korenaga M, Hashiguchi Y. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimonite. J Antimicrob Chemother 2007; 59: 1123-1129 (Pubitemid 47073322)
31. Murray HW, Flanders KC, Donaldson DD, et al. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect Immun 2005; 73: 3903-3911
32. Sergiev VP, Shuikina EE, Kuznetsov VP, et al. The use of leukinferon in treating zoonotic cutaneous leishmaniasis. Medtsinskaia Parasitollogia i Parasitarnye Bolezni (Moskva) 1993; 1: 42-43
33. Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimonate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007; 15: 1549-1554 (Pubitemid 46871500)
34. Firooz A, Khamesipour A, Ghoorchi MH, et al. Imiquimod in combination with meglumine antimonite for cutaneous leishmaniasis. Arch Dermatol 2006; 142: 1575-1579
35. Bhowmick S, Ravidran R, Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible Balb/c mice infected with Leishmania donovani. Infect Immun 2008; 76: 1003-1015
36. Shimizu Y, Takagi H, Nakayama T, et al. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in Balb/c mice through uptake by peritoneal macrophages. Parasite Immunol 2007; 29: 229-239 (Pubitemid 46596114)
37. Badiee A, Jaafari MR, Khamesipour A. Leishmania major: Immune response in Balb/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Exp Parasitol 2007; 115: 127-134 (Pubitemid 44820050)
38. Kshirsagar NA, Pandya SK, Kirodian GB, Sanath S. Liposomal drug delivery system from laboratory to clinic. J Postgrad Med 2005; 51 (Suppl 1): S5-15.
39. Carrion J, Nieto A, Soto M, Alonso C. Adoptive transfer of dentritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniasis in Balb/c mice. Microb Infect 2007; 9: 735-743 (Pubitemid 46660686)
40. Ghosh M, Pal C, Ray M, Maitra S, Mandal L, Bandyopadhyay S. Dentritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J Immunol 2003; 170: 5625-5629 (Pubitemid 36617853)